IMCR FY 2025 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$298M+20.1% YoY

Gross Profit

$291M97.9% margin

Operating Income

-$34M-11.3% margin

Net Income

-$26M-8.9% margin

EPS (Diluted)

$-0.53

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$686M

Stockholders' Equity

$381M

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$298M	$248M	+20.1%
Gross Profit	$291M	$239M	+21.7%
Operating Income	-$34M	-$56M	+40.1%
Net Income	-$26M	-$41M	+35.3%